Meghan Sharp

Ms. Sharp is a member of BP's corporate venture team. Investments span the BP Group, focused on emerging, strategic technologies in five areas:bioenergy and biomaterials; energy efficiency and storage; carbon management; renewable power; and oil and gas. Ms. Sharp focuses on bio-based investments for the team and serves on the board of Chromatin Inc., Biosynthetic Technologies, Verdezyne, and Taxon Biosciences. Ms. Sharp received her Ph.D. in microbial genetics from the University of California, San Francisco, performed post-doctoral work in plant genetics at the University of Chicago and the Carnegie Institution of Washington at Stanford University, and received her MBA from Columbia University.